These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15989551)

  • 1. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents.
    Neckers L; Neckers K
    Expert Opin Emerg Drugs; 2002 Oct; 7(2):277-88. PubMed ID: 15989551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
    Koga F; Kihara K; Neckers L
    Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat shock protein 90 is a rational molecular target in breast cancer.
    Neckers L
    Breast Dis; 2002; 15():53-60. PubMed ID: 15687645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 inhibitors as novel cancer chemotherapeutic agents.
    Neckers L
    Trends Mol Med; 2002; 8(4 Suppl):S55-61. PubMed ID: 11927289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
    Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
    Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
    Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
    Neckers L
    Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock protein 90.
    Neckers L; Ivy SP
    Curr Opin Oncol; 2003 Nov; 15(6):419-24. PubMed ID: 14624223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
    Neckers L
    Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.
    Ibrahim NO; Hahn T; Franke C; Stiehl DP; Wirthner R; Wenger RH; Katschinski DM
    Cancer Res; 2005 Dec; 65(23):11094-100. PubMed ID: 16322259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Hsp90 for the treatment of cancer.
    Drysdale MJ; Brough PA; Massey A; Jensen MR; Schoepfer J
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
    Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
    Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
    Workman P
    Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
    Tsutsumi S; Neckers L
    Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaperoning oncogenes: Hsp90 as a target of geldanamycin.
    Neckers L
    Handb Exp Pharmacol; 2006; (172):259-77. PubMed ID: 16610363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.